Aquestive Therapeutics (NASDAQ:AQST) Stock Attempts To Recover: Will It Continue?

Aquestive Therapeutics (NASDAQ:AQST) gained 3% after announcing that the US FDA had accepted its Libervant Buccal Film NDA resubmission filing for seizure clusters management. The FDA gave a Prescription Drug User Fee Act target date of December 23, 2021.

CEP Keth Kendall said that they are delighted with the decision by the FDA to revive the company’s Libervant NDA. Kendall said they believe that the acceptance highlights the unmet medical need of the underserved refractory epilepsy patient’s population for a novel and non-invasive seizure clusters management product. 

The CEO said that the company plans Libervant’s commercial launch in 1H 2021 if it is approved for market access. Aquestive is committed to offer treatment for this unmet medical need and enhance the quality of life of patients suffering from the disease.  In September last year, the FDA gave the company a Complete Response Letter and completed Type A meeting in November, and more guidance from the FDA was issued in February this year. So in the coming months, AQST is a stock to watch.

Market Reaction:

On Tuesday, AQST stock moved up 2.80% at $3.68 with more than 428k shares, compared to its average volume of 604k shares. The stock has moved within a range of $3.4700 – 3.7000 after opening the trade at $3.57. Over the past 52-week, the stock has been trading within a range of $3.1700 – 9.4650.